Literature DB >> 28391416

Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn's Disease.

Aleksandra Piechota-Polanczyk1,2, Marcin Włodarczyk3,4, Aleksandra Sobolewska-Włodarczyk3,5, Mateusz Jonakowski3, Andrzej Pilarczyk3, Krystyna Stec-Michalska5, Maria Wiśniewska-Jarosińska5, Jakub Fichna3.   

Abstract

BACKGROUND: Cyclophilin A (CyPA) is an immunomodulatory protein, high expression of which correlates with poor outcome of patients with inflammatory diseases. However, its role in inflammatory bowel disease (IBD) has not been studied. AIM: This study analyzes the correlation between cyclophilin A, matrix metalloproteinase (MMP)-9, and tissue inhibitor of MMP (TIMP)/MMP-9 complexes in the inflamed and non-inflamed colon mucosa of UC and CD patients.
METHODS: Serum and biopsy specimens from inflamed and non-inflamed colonic mucosa of 38 patients with IBD (19 with UC and 19 with CD) and 16 controls were included in our study. We measured serum and tissue level of CyPA, and tissue level of TNF-α, MMP-9, TIMP-1/MMP-9, and TIMP-2/MMP-9 using ELISA method.
RESULTS: Our results indicated that serum, but not tissue CyPA is increased in UC, rather than in CD patients, compared to the control. The increase correlated with higher tissue concentration of MMP-9 and TNF-α, especially in the UC group. Moreover, we observed significantly higher level of TIMP-1/MMP-9 in UC and CD group, which overlapped with the change in MMP-9. There was no change in TIMP-2/MMP-9 in the analyzed groups.
CONCLUSION: The current study suggests that serum CyPA may be an independent additional marker of IBD, especially of UC. Higher CyPA level may be followed by increased MMP-9 in those patients. However, further studies are necessary to verify the role of CyPA in IBD development.

Entities:  

Keywords:  Crohn’s disease; Cyclophilin A; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28391416     DOI: 10.1007/s10620-017-4568-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Authors:  Q Gao; M J W Meijer; F J G M Kubben; C F M Sier; L Kruidenier; W van Duijn; M van den Berg; R A van Hogezand; C B H W Lamers; H W Verspaget
Journal:  Dig Liver Dis       Date:  2005-08       Impact factor: 4.088

Review 2.  Matrix metalloproteinases as modulators of inflammation.

Authors:  Anne M Manicone; John K McGuire
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

3.  Determination of protein by a modified Lowry procedure in the presence of some commonly used detergents.

Authors:  E Cadman; J R Bostwick; J Eichberg
Journal:  Anal Biochem       Date:  1979-07-01       Impact factor: 3.365

4.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

5.  Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice.

Authors:  Alfredo Santana; Carlos Medina; Maria-Cristina Paz-Cabrera; Federico Díaz-Gonzalez; Esther Farré; Antonio Salas; Marek-W Radomski; Enrique Quintero
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 6.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

7.  Extracellular cyclophilin-A stimulates ERK1/2 phosphorylation in a cell-dependent manner but broadly stimulates nuclear factor kappa B.

Authors:  Karim Bahmed; Curtis Henry; Michael Holliday; Jasmina Redzic; Madalina Ciobanu; Fengli Zhang; Colin Weekes; Robert Sclafani; James Degregori; Elan Eisenmesser
Journal:  Cancer Cell Int       Date:  2012-07-04       Impact factor: 5.722

8.  Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis.

Authors:  Sarah R Calabro; Annette E Maczurek; Alison J Morgan; Thomas Tu; Victoria W Wen; Christine Yee; Auvro Mridha; Maggie Lee; William d'Avigdor; Stephen A Locarnini; Geoffrey W McCaughan; Fiona J Warner; Susan V McLennan; Nicholas A Shackel
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

9.  Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Authors:  Katarzyna Jakubowska; Anna Pryczynicz; Joanna Januszewska; Iwona Sidorkiewicz; Andrzej Kemona; Andrzej Niewiński; Łukasz Lewczuk; Bogusław Kędra; Katarzyna Guzińska-Ustymowicz
Journal:  Dis Markers       Date:  2016-06-26       Impact factor: 3.434

10.  Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis.

Authors:  Y Yang; N Lu; J Zhou; Z-N Chen; P Zhu
Journal:  Rheumatology (Oxford)       Date:  2008-06-21       Impact factor: 7.580

View more
  3 in total

1.  Thalidomide Prevented and Ameliorated Pathogenesis of Crohn's Disease in Mice via Regulation of Inflammatory Response and Fibrosis.

Authors:  Hongjin Chen; Haixia Xu; Lijiao Luo; Lichao Qiao; Yaohui Wang; Minmin Xu; Youran Li; Ping Zhu; Bolin Yang
Journal:  Front Pharmacol       Date:  2019-12-13       Impact factor: 5.810

Review 2.  How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?

Authors:  Ghislain Opdenakker; Séverine Vermeire; Ahmed Abu El-Asrar
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

Review 3.  The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.

Authors:  Lifang Liang; Rongxiao Lin; Ying Xie; Huaqing Lin; Fangyuan Shao; Wen Rui; Hongyuan Chen
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.